EFTX-G12V: a novel KRASG12V-selective RNAi therapeutic.
IF 19.9
1区 医学
Q1 PHARMACOLOGY & PHARMACY
引用次数: 0
Abstract
KRASG12V-driven cancers remain therapeutically elusive. Recently, Stanland and colleagues developed EFTX-G12V, a GE11-conjugated small interfering RNA (siRNA) that selectively silences KRASG12V and achieves tumor regression by inhibiting oncogenic signaling and angiogenesis and enhancing anti-tumor immunity. EFTX-G12V represents an innovative RNAi-based precision oncology strategy for previously undruggable oncogenic mutations.
EFTX-G12V：一种新的krasg12v选择性RNAi治疗药物。
krasg12v驱动的癌症在治疗上仍然难以捉摸。最近，Stanland及其同事开发了EFTX-G12V，这是一种ge11偶联的小干扰RNA (siRNA)，它可以选择性地沉默KRASG12V，通过抑制致癌信号和血管生成以及增强抗肿瘤免疫来实现肿瘤消退。EFTX-G12V代表了一种创新的基于rnai的精确肿瘤学策略，用于治疗以前无法治疗的致癌突变。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
CiteScore
23.90
自引率
0.70%
发文量
132
审稿时长
6-12 weeks
期刊介绍：
Trends in Pharmacological Sciences (TIPS) is a monthly peer-reviewed reviews journal that focuses on a wide range of topics in pharmacology, pharmacy, pharmaceutics, and toxicology. Launched in 1979, TIPS publishes concise articles discussing the latest advancements in pharmacology and therapeutics research.
The journal encourages submissions that align with its core themes while also being open to articles on the biopharma regulatory landscape, science policy and regulation, and bioethics.
Each issue of TIPS provides a platform for experts to share their insights and perspectives on the most exciting developments in the field. Through rigorous peer review, the journal ensures the quality and reliability of published articles.
Authors are invited to contribute articles that contribute to the understanding of pharmacology and its applications in various domains. Whether it's exploring innovative drug therapies or discussing the ethical considerations of pharmaceutical research, TIPS provides a valuable resource for researchers, practitioners, and policymakers in the pharmacological sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
